科研之友
微信
新浪微博
Facebook
分享链接
摘要
Recently published data from four phase 3 safety and efficacy trials show that the synthetic peptide-based, erythropoietin mimetic, peginesatide, is noninferior to conventional erythropoiesis-stimulating agents in increasing haemoglobin levels in patients with chronic kidney disease (CKD). However, peginesatide therapy increased the risk of a combined cardiovascular end point in patients with CKD not on dialysis. Eckardt, K.-U. Nat. Rev. Nephrol. 9, 192-193 (2013); published online 12 March 2013; doi:10.1038/nrneph.2013.42
- 出版日期2013-4
